Table 2.

Randomized trial concerning high-intermediate risk.

R Maggi et al. [33]	A randomized controlled trial	A total of 345 patients were randomly assigned; 168 to external RT and 177 to adjuvant CT	To evaluate whether adjuvant CT confers an advantage for overall and progression-free survival and on the incidence of local and distant relapses over standard pelvic RT, in high-risk patients without residual tumor.	First evidence of the possibility to combine RT and CT.	No improvement in PFS and OS in patients treated with one or the other treatment protocol. Both therapeutic approaches were associated with acceptable toxicities.
Nobuyuki Susumu et al. [34]	A randomized phase III trial	A total of 385 patients were randomly assigned; 193 to pelvic radiation therapy (PRT) and 192 to cyclophosphamide–doxorubicin–cisplatin (CAP) chemotherapy.	To establish an optimal adjuvant therapy for intermediate- and high-risk endometrial cancer patients.	Adjuvant chemotherapy may be a useful alternative to radiotherapy for intermediate-risk endometrial cancer.	No statistically significant differences in survivals in the two regimens. Adverse effects were not significantly increased in a platinum-based combined chemo- therapy group. Chemotherapy significantly improved PFS and OS in HIR patients, versus pelvic radiation.
Thomas Hogberg et al. [35]	Two randomized trial	A total of 383 patients were randomly assigned; 183 to RT and 187 to RT-CT; a total of 157 patients were randomly assigned; 76 to RT and 80 to RT-CT.	To evaluate if sequential combination of chemotherapy and radiotherapy improves progression-free survival (PFS) in high-risk endometrial cancer.	The sequential addition of CT to RT was associated with a significant 36% reduction in the risk of relapse or death and a significant 49% reduction.	Addition of adjuvant chemotherapy to radiation improves progression-free survival in operated endometrial cancer patients with no residual tumor and a high-risk profile.
Marcus E. Randall et al. [36]	A randomized phase III trial	A total of 601 patients were randomly assigned; 301 to PRT and 300 to vaginal cuff brachytherapy plus three cycles of carboplatin and paclitaxel repeated every 3 weeks.	To determine if vaginal cuff brachytherapy and chemotherapy (VCB/C) increases recurrence-free survival (RFS) compared with PRT in high-intermediate and high-risk early-stage endometrial carcinoma.	Post-operative adjuvant therapy with VCB/C was not superior to EBRT and was associated with more frequent and severe acute toxicity.	Pelvic RT remains an appropriate treatment for high-risk early-stage endometrial carcinoma